Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|October 28, 2024

Key Takeaways on the Future of HER2 in NSCLC

Key Takeaways

Panelists conclude by highlighting key takeaways in the management of NSCLC.

Episodes in this series

4 KOLs are featured in this series

EP. 1 Introduction and Current Landscape of HER2 in NSCLC

4 KOLs are featured in this series

EP. 2 Safety and Efficacy of HER2-Directed ADCs for NSCLC

4 KOLs are featured in this series

EP. 3 Treatment Considerations for Patients With HER2+ NSCLC

4 KOLs are featured in this series

EP. 4 Latest Advances and Therapies for HER2+ NSCLC

4 KOLs are featured in this series

EP. 5 Unmet Needs and Clinical Considerations for HER2+ NSCLC

4 KOLs are featured in this series

EP. 6 Integrating HER2-Directed Therapies Into Standard Care for NSCLC

4 KOLs are featured in this series

EP. 7 HER2- Mutation Testing Considerations and Timing

4 KOLs are featured in this series

EP. 8 Factors Impacting Use of HER2 Therapies for NSCLC

4 KOLs are featured in this series

EP. 9 Incorporating Real-World Evidence for HER2+ NSCLC

4 KOLs are featured in this series

EP. 10 Key Takeaways on the Future of HER2 in NSCLC

4 KOLs are featured in this series

EP. 11 Real-World Outcomes in HER2-Positive NSCLC

4 KOLs are featured in this series

EP. 12 Managing Treatment Challenges in HER2-Directed Therapies

4 KOLs are featured in this series

EP. 13 Emerging Horizons in HER2-Directed NSCLC Treatments

4 KOLs are featured in this series

EP. 14 Patient Selection and Personalized Treatment Strategies

4 KOLs are featured in this series

EP. 15 Navigating Healthcare Access and Decision-Making

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Irina Murakhovskaya | Image Credit: Montefiore Einstein

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

ByBrooke McCormick,Irina Murakhovskaya, MD

June 26th 2026

CRC animation | Image Credit: Thipphaphone - stock.adobe.com

Early-Life, Parental Factors May Help Explain Rising Early-Onset CRC Rates

ByBrooke McCormick

June 26th 2026

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

HR-Positive Breast Cancer: Clinical Use of Oral SERDs in Combination vs Monotherapy

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.

HR-Positive Breast Cancer: Evolving Role of ESR1 Mutations in Endocrine Resistance

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

Stamp that says "FDA Approved" in blue ink. | Image Credit: Surendra - stock.adobe.com

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

ByElla Hohmann, MS

June 25th 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma

Health Equity & Access Weekly Roundup: June 26, 2026

ATTR-CM Incidence, Prevalence Rose Sharply in the US